Q-omics provides the consensus-scored TSPYL4 profile across patient tissues and cancer cell-line models. TSPYL4 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TSPYL4 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TSPYL4 RNA expression shows 20,945 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where TSPYL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPYL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPYL4 survival associations across molecular data types. TSPYL4 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPYL4 RNA expression–survival associations across cancer types. High TSPYL4 expression shows unfavorable associations in STAD, but favorable associations in KIRC, LGG, LUAD, UCS and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TSPYL4 RNA expression.
This table summarizes TSPYL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPYL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPYL4 shows lower tumor expression in KICH, KIRC, THCA, UCEC and LUAD and higher tumor expression in CHOL. The KICH box plot shows higher TSPYL4 RNA expression in normal versus tumor tissue (log2 FC = −1.817, t-test p < 0.001).
This table shows molecular features associated with TSPYL4 in patient tissues and cancer cell lines. In patient samples, TSPYL4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPYL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
